Roche Gains Place in NASH Race with Purchase of Jecure Therapeutics | Enterpreneurship

Want create site? Find Free WordPress Themes and plugins.

is acquiring San Diego startup , with hopes of turning Jecure’s early research into a drug or drugs that treat the liver disease .

serverpoint hosting banner

Through its South San Francisco, CA-based Genentech division, the Swiss pharmaceutical giant will acquire Jecure, whose work has yet to reach clinical studies, the companies announced Tuesday. No financial terms were disclosed, but a Genentech spokesman said it was an all-cash deal.

Nonalcoholic steatohepatitis, or NASH, is a serious form of fatty liver disease that causes inflammation and scarring in the organ. There are no FDA-approved drugs for NASH, and in cases where the condition… Read more »

UNDERWRITERS AND PARTNERS

Did you find apk for android? You can find new Free Android Games and apps.

You might also like More from author

Leave A Reply

Your email address will not be published.